Published in J Exp Med on May 01, 1983
Epitopes of herpes simplex virus type 1 glycoprotein gC are clustered in two distinct antigenic sites. J Virol (1985) 1.60
Antigenic variation (mar mutations) in herpes simplex virus glycoprotein B can induce temperature-dependent alterations in gB processing and virus production. J Virol (1986) 1.39
Expression of herpes simplex virus 1 glycoprotein B by a recombinant vaccinia virus and protection of mice against lethal herpes simplex virus 1 infection. Proc Natl Acad Sci U S A (1987) 1.26
Herpes simplex virus 1 protein kinase Us3 phosphorylates viral envelope glycoprotein B and regulates its expression on the cell surface. J Virol (2008) 1.19
Specificity of human natural killer cells in limiting dilution culture for determinants of herpes simplex virus type 1 glycoproteins. J Virol (1986) 1.16
Innate and adaptive immune responses to herpes simplex virus. Viruses (2009) 1.14
Human T-lymphocyte response in vitro to synthetic peptides of herpes simplex virus glycoprotein D. Proc Natl Acad Sci U S A (1985) 1.12
Immediate-early gene expression is sufficient for induction of natural killer cell-mediated lysis of herpes simplex virus type 1-infected fibroblasts. J Virol (1991) 1.04
Re-evaluating the role of natural killer cells in innate resistance to herpes simplex virus type 1. Virol J (2005) 0.95
Effects of phosphorylation of herpes simplex virus 1 envelope glycoprotein B by Us3 kinase in vivo and in vitro. J Virol (2010) 0.94
Role of the herpes simplex virus 1 Us3 kinase phosphorylation site and endocytosis motifs in the intracellular transport and neurovirulence of envelope glycoprotein B. J Virol (2011) 0.92
Lysis of varicella zoster virus infected cells by lymphocytes from normal humans and immunosuppressed pediatric leukaemic patients. Clin Exp Immunol (1985) 0.89
Cocaine increases natural killer cell activity. J Clin Invest (1986) 0.85
In vivo expression of perforin by natural killer cells during a viral infection. Studies on uveitis produced by herpes simplex virus type I. Am J Pathol (1990) 0.83
Cellular interactions in the lysis of varicella-zoster virus infected human fibroblasts. Clin Exp Immunol (1986) 0.81
Bovine naturally cytolytic cell activation against bovine herpes virus type 1-infected cells does not require late viral glycoproteins. Immunology (1989) 0.81
Natural killer-mediated lysis of some but not all HSV-1- or VSV-infected targets requires the participation of HLA-DR-positive accessory cells. Immunology (1991) 0.79
Human T helper cells specific for antigens of typhus group rickettsiae enhance natural killer cell activity in vitro. Infect Immun (1986) 0.78
Heterogeneity amongst natural killer cells revealed by limiting dilution culture; selectivity against virus-infected and tumour cell targets. Immunology (1993) 0.75
The Fc Domain of Immunoglobulin Is Sufficient to Bridge NK Cells with Virally Infected Cells. Immunity (2017) 0.75
Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g. Scand J Clin Lab Invest Suppl (1968) 60.35
Membrane proteins specified by herpes simplex viruses. I. Identification of four glycoprotein precursors and their products in type 1-infected cells. J Virol (1976) 8.73
A differentiation antigen of human NK and K cells identified by a monoclonal antibody (HNK-1). J Immunol (1981) 8.17
Separation of mouse spleen cells by passage through columns of sephadex G-10. J Immunol Methods (1974) 7.19
Epstein-Barr virus-specific IgA serum antibodies as an outstanding feature of nasopharyngeal carcinoma. Int J Cancer (1976) 3.36
Natural killer cells: characteristics and regulation of activity. Immunol Rev (1979) 3.14
Cross-reaction of a rat-anti-mouse phagocyte-specific monoclonal antibody (anti-Mac-1) with human monocytes and natural killer cells. J Immunol (1981) 2.94
Do natural killer cells engage in regulated reactions against self to ensure homeostasis? Immunol Rev (1979) 2.01
Cell-mediated cytotoxicity against virus-infected target cells in humans. II. Interferon induction and activation of natural killer cells. J Immunol (1978) 1.99
Natural killing of herpes simplex virus type 1-infected target cells: normal human responses and influence of antiviral antibody. Infect Immun (1979) 1.94
Method for induction of mutations in physically defined regions of the herpes simplex virus genome. J Virol (1981) 1.89
Mechanism of rejection of virus persistently infected tumor cells by athymic nude mice. J Exp Med (1979) 1.81
Cell-mediated cytotoxicity against virus-infected target cells in humans. I. Characterization of the effector lymphocyte. J Immunol (1978) 1.58
Mutant analysis of herpes simplex virus-induced cell surface antigens: resistance to complement-mediated immune cytolysis. J Virol (1980) 1.48
Natural cell-mediated immunity during viral infections. Curr Top Microbiol Immunol (1981) 1.40
Effect of virus infections on target cell susceptibility to natural killer cell-mediated lysis. J Immunol (1980) 1.27
Role of interferon in natural kill of HSV-1-infected fibroblasts. J Immunol (1982) 1.22
Delineation of an effector population responsible for natural killing and antibody-dependent cellular cytotoxicity in man. Clin Immunol Immunopathol (1981) 1.20
Glycolipid expression in lymphoma cell variants: chemical quantity, immunologic reactivity, and correlations with susceptibility to NK cells. J Immunol (1981) 1.20
Surface antigens on mouse natural killer cells: use of monoclonal antibodies to inhibit or to enrich cytotoxic activity. J Immunol (1981) 1.17
Resistance to herpes simplex virus - type 1 (HSV-1). Curr Top Microbiol Immunol (1981) 1.17
Natural cytotoxic cells against solid tumors in mice: blocking of cytotoxicity by D-mannose. Proc Natl Acad Sci U S A (1980) 1.16
Deficiency of natural killer cell activity in patients with chronic lymphocytic leukemia. Int J Cancer (1981) 1.16
In vitro generation of human cytotoxic lymphocytes by virus. Viral glycoproteins induce nonspecific cell-mediated cytotoxicity without release of interferon. J Exp Med (1981) 1.13
Subpopulations of human T lymphocytes. VII. Cellular basis of concanavalin A-induced T cell-mediated suppression of immunoglobulin production by B lymphocytes from normal humans. Cell Immunol (1979) 1.13
Inhibition of the growth of lymphoid tumours in syngeneic athymic (nude) mice. Int J Cancer (1977) 1.11
A subset of human cells isolated and characterized by monoclonal antibodies. Eur J Immunol (1981) 1.06
Aquanititave semimicro, semiautomated colorimetric assay for interferon. J Lab Clin Med (1977) 1.04
Cytomegalovirus-specific cytotoxicity mediated by non-T lymphocytes from peripheral blood of normal volunteers. Infect Immun (1981) 1.03
Induction of natural killer cells by herpes-simplex virus type 2 in resistant and sensitive inbred mouse strains. Immunobiology (1981) 1.03
Extravascular natural cytotoxicity in man: Anti-K562 activity of lymph-node and tumour-infiltrating lymphocytes. Int J Cancer (1981) 1.01
Increased sensitivity of human lymphoid lines to natural killer cells after induction of the Epstein-Barr viral cycle by superinfection or sodium butyrate. J Exp Med (1980) 1.00
Induction of natural killer cells during murine influenza virus infection. Immunobiology (1981) 1.00
Correlation of glycosphingolipids and sialic acid in YAC-1 lymphoma variants with their sensitivity to natural killer-cell-mediated lysis. Int J Cancer (1981) 0.97
Natural cytotoxicity of murine cytomegalovirus-infected cells mediated by mouse lymphoid cells: role of interferon in the endogenous natural cytotoxicity reaction. Infect Immun (1982) 0.94
Resistance of nude mice to herpes simplex virus and correlation with in vitro production of interferon. Cell Immunol (1979) 0.94
Natural killing of cytomegalovirus-infected fibroblasts by human mononuclear leucocytes. Clin Exp Immunol (1981) 0.93
Phylogeny of NK cell reactivity against human and nonhuman primate lymphoblastoid cell lines: evolving and conserved target antigens. J Immunol (1981) 0.91
Suppression of natural killer activity and antibody-dependent cellular cytotoxicity by cultured human lymphocytes. J Immunol (1981) 0.88
Enhancement of human natural killer cells by interferon requires RNA and protein synthesis. Clin Immunol Immunopathol (1982) 0.87
Naturally occurring lymphocyte-mediated immunity to endogenous type-C virus in the mouse. Blocking of the lymphocyte reactivity with antisera to the virus. J Exp Med (1979) 0.85
Inhibition of effector cell functions in natural killer cell activity (NK) and antibody-dependent cellular cytotoxicity (ADCC) in mice by normal and cancer sera. Int J Cancer (1980) 0.84
Surveillance of primitive cells by natural killer cells. Curr Top Microbiol Immunol (1981) 0.84
Further characterization of natural killer cells induced by Kunjin virus. Aust J Exp Biol Med Sci (1980) 0.82
In vitro induction of human cell-mediated cytotoxicity directed against herpes simplex virus-infected cells. Kinetics in normal donors and patients with recurrent herpes labialis. J Clin Lab Immunol (1981) 0.82
Effector cell sensitivity to sugar moieties. I. Inhibition of human natural killer cell activity by monosaccharides. Immunobiology (1981) 0.80
In vitro production of immune interferon by spleen cells of mice immunized with herpes simplex virus. Cell Immunol (1978) 0.77
CpG motifs in bacterial DNA trigger direct B-cell activation. Nature (1995) 12.24
Cloning of herpes simplex virus type 1 sequences representing the whole genome. J Virol (1981) 5.66
Suppressor cell activity after concanavalin A treatment of lymphocytes from normal donors. J Exp Med (1976) 5.50
Purification and characterization of colicin E1. J Biol Chem (1971) 4.27
Transcriptional and genetic analyses of the herpes simplex virus type 1 genome: coordinates 0.29 to 0.45. J Virol (1984) 4.09
Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics. Nat Med (2001) 4.02
Neutralizing monoclonal antibodies specific for herpes simplex virus glycoprotein D inhibit virus penetration. J Virol (1987) 3.74
A simple, rapid method for the purification of poly A+ RNA. Biotechniques (1988) 3.22
High-frequency transfer of cloned herpes simplex virus type 1 sequences to mammalian cells by protoplast fusion. Mol Cell Biol (1981) 2.97
Physical mapping of the mutation in an antigenic variant of herpes simplex virus type 1 by use of an immunoreactive plaque assay. J Virol (1983) 2.96
Mutations in herpes simplex virus type 1 genes encoding VP5 and VP23 abrogate capsid formation and cleavage of replicated DNA. J Virol (1993) 2.79
Transcriptional control signals of a herpes simplex virus type 1 late (gamma 2) gene lie within bases -34 to +124 relative to the 5' terminus of the mRNA. Mol Cell Biol (1986) 2.65
The pseudorabies virus gII gene is closely related to the gB glycoprotein gene of herpes simplex virus. J Virol (1987) 2.58
Rapid identification of nonessential genes of herpes simplex virus type 1 by Tn5 mutagenesis. Science (1987) 2.57
Expression of herpes simplex virus beta and gamma genes integrated in mammalian cells and their induction by an alpha gene product. Mol Cell Biol (1983) 2.15
A specific 15-bp TATA box promoter element is required for expression of a herpes simplex virus type 1 late gene. Genes Dev (1988) 2.11
Progressive liver injury in chronic hepatitis C infection correlates with increased intrahepatic expression of Th1-associated cytokines. Hepatology (1996) 2.01
Monoclonal antibodies define a domain on herpes simplex virus glycoprotein B involved in virus penetration. J Virol (1988) 1.94
Immune interactions with cells infected with herpes simplex virus: antibodies to radioiodinated surface antigens. J Immunol (1977) 1.94
Possible role of Fc receptors on cells infected and transformed by herpesvirus: escape from immune cytolysis. Infect Immun (1978) 1.93
Relapse in sexual behavior among homosexual men: a 2-year follow-up from the Chicago MACS/CCS. AIDS (1991) 1.90
Method for induction of mutations in physically defined regions of the herpes simplex virus genome. J Virol (1981) 1.89
A novel latency-active promoter is contained within the herpes simplex virus type 1 UL flanking repeats. J Virol (1994) 1.86
Real-time reverse transcriptase-polymerase chain reaction (RT-PCR) for measurement of cytokine and growth factor mRNA expression with fluorogenic probes or SYBR Green I. Immunol Cell Biol (2001) 1.85
Inversion events in the HSV-1 genome are directly mediated by the viral DNA replication machinery and lack sequence specificity. Cell (1988) 1.84
The CH series of murine B cell lymphomas: neoplastic analogues of Ly-1+ normal B cells. Immunol Rev (1986) 1.81
Antigenic analysis of a major neutralization site of herpes simplex virus glycoprotein D, using deletion mutants and monoclonal antibody-resistant mutants. J Virol (1988) 1.74
Recruitment of CD40 and tumor necrosis factor receptor-associated factors 2 and 3 to membrane microdomains during CD40 signaling. J Biol Chem (2000) 1.70
Antihyperalgesic effects of infection with a preproenkephalin-encoding herpes virus. Proc Natl Acad Sci U S A (1999) 1.68
Regulation of the herpes simplex virus type 1 late (gamma 2) glycoprotein C gene: sequences between base pairs -34 to +29 control transient expression and responsiveness to transactivation by the products of the immediate early (alpha) 4 and 0 genes. Nucleic Acids Res (1987) 1.68
Intraarticular expression of biologically active interleukin 1-receptor-antagonist protein by ex vivo gene transfer. Proc Natl Acad Sci U S A (1993) 1.65
HSV-mediated gene transfer of vascular endothelial growth factor to dorsal root ganglia prevents diabetic neuropathy. Gene Ther (2005) 1.63
Syncytium-inducing mutations localize to two discrete regions within the cytoplasmic domain of herpes simplex virus type 1 glycoprotein B. J Virol (1993) 1.63
A short course of methylprednisolone immunosuppression inhibits both rejection and spontaneous acceptance of rat liver allografts. Transplantation (2001) 1.61
Amino acid sequence studies on artiodactyl fibrinopeptides. I. Dromedary camel, mule deer, and cape buffalo. Arch Biochem Biophys (1967) 1.60
Epitopes of herpes simplex virus type 1 glycoprotein gC are clustered in two distinct antigenic sites. J Virol (1985) 1.60
Increased expression of HLA-DR antigens on renal tubular cells in renal transplants: relevance to the rejection response. Lancet (1984) 1.57
Identification of mar mutations in herpes simplex virus type 1 glycoprotein B which alter antigenic structure and function in virus penetration. J Virol (1989) 1.52
Competitive quantitative PCR analysis of herpes simplex virus type 1 DNA and latency-associated transcript RNA in latently infected cells of the rat brain. J Virol (1994) 1.51
Cord blood mononuclear cell cytokine responses in relation to maternal house dust mite allergen exposure. Clin Exp Allergy (2002) 1.51
Suppression of immunoglobulin synthesis and secretion by peripheral blood lymphocytes from normal donors. Proc Natl Acad Sci U S A (1977) 1.50
Varicella-zoster virus Fc receptor gE glycoprotein: serine/threonine and tyrosine phosphorylation of monomeric and dimeric forms. J Virol (1997) 1.50
Antigenic and functional analysis of a neutralization site of HSV-1 glycoprotein D. Virology (1990) 1.49
Differential signaling and tumor necrosis factor receptor-associated factor (TRAF) degradation mediated by CD40 and the Epstein-Barr virus oncoprotein latent membrane protein 1 (LMP1). J Exp Med (2001) 1.48
Patient protection in cancer chemotherapy. JAMA (1966) 1.48
Mutant analysis of herpes simplex virus-induced cell surface antigens: resistance to complement-mediated immune cytolysis. J Virol (1980) 1.48
Induced differentiation of a transformed clone of Ly-1+ B cells by clonal T cells and antigen. Proc Natl Acad Sci U S A (1986) 1.46
Passive immune protection by herpes simplex virus-specific monoclonal antibodies and monoclonal antibody-resistant mutants altered in pathogenicity. J Virol (1985) 1.45
Bacteria as an Indicator of Formation of Antibodies by Single Spleen Cells in Agar. Science (1965) 1.42
HSV trafficking and development of gene therapy vectors with applications in the nervous system. Gene Ther (2005) 1.42
Antinociceptive effect of a genomic herpes simplex virus-based vector expressing human proenkephalin in rat dorsal root ganglion. Gene Ther (2001) 1.41
Antigenic variation (mar mutations) in herpes simplex virus glycoprotein B can induce temperature-dependent alterations in gB processing and virus production. J Virol (1986) 1.39
Gene transfer to synoviocytes: prospects for gene treatment of arthritis. DNA Cell Biol (1992) 1.37
Effect of cross-immunization on monotypic antibody responses to herpes simplex virus types 1 and 2. J Immunol (1976) 1.37
Two herpes simplex virus type 1 latency-active promoters differ in their contributions to latency-associated transcript expression during lytic and latent infections. J Virol (1995) 1.37
Gene transfer to interfere with TNFalpha signaling in neuropathic pain. Gene Ther (2007) 1.37
Deletion of multiple immediate-early genes from herpes simplex virus reduces cytotoxicity and permits long-term gene expression in neurons. Gene Ther (1998) 1.36
Gene transfer to neurons using herpes simplex virus-based vectors. Annu Rev Neurosci (1996) 1.35
Localization of a functional site on herpes simplex virus type 1 glycoprotein C involved in binding to cell surface heparan sulphate. J Gen Virol (1994) 1.35
Molecular basis of the glycoprotein C-negative phenotypes of herpes simplex virus type 1 mutants selected with a virus-neutralizing monoclonal antibody. J Virol (1986) 1.33
Clinical trial to assess the safety, feasibility, and efficacy of transferring a potentially anti-arthritic cytokine gene to human joints with rheumatoid arthritis. Hum Gene Ther (1996) 1.31
Intranasal interferon-alpha 2b for seasonal prophylaxis of respiratory infection. J Infect Dis (1986) 1.30
A cell-free recombination system for site-specific integration of multigenic shuttle plasmids into the herpes simplex virus type 1 genome. J Virol (1992) 1.29
Localization on the herpes simplex virus type 1 genome of a region encoding proteins involved in adsorption to the cellular receptor. J Virol (1990) 1.26
Microbiological studies on septicemic bullfrogs (Rana catesbeiana). Am J Vet Res (1974) 1.26
Persistence of herpes simplex virus genes in cells of neuronal origin. J Virol (1980) 1.25
Membrane-bound CD154, but not CD40-specific antibody, mediates NF-kappaB-independent IL-6 production in B cells. Eur J Immunol (1999) 1.25
Adenoviral transfer of the viral IL-10 gene periarticularly to mouse paws suppresses development of collagen-induced arthritis in both injected and uninjected paws. J Immunol (1999) 1.24
Infection by herpes simplex virus and cells of nervous system origin: characterization of a non-permissive interaction. J Gen Virol (1978) 1.24
Automobile emissions are statistically gamma distributed. Environ Sci Technol (1994) 1.24
Adhesion of type A Pasteurella mulocida to rabbit pharyngeal cells and its possible role in rabbit respiratory tract infections. Infect Immun (1982) 1.23
The RR1 gene of herpes simplex virus type 1 is uniquely trans activated by ICP0 during infection. J Virol (1993) 1.22
Complement-mediated cytolysis of HSV-1 and HSV-2 infected cells: plasma membrane antigens reactive with type-specific and cross-reactive antibody. J Gen Virol (1978) 1.21
Herpes simplex virus type 1 ICP0 protein does not accumulate in the nucleus of primary neurons in culture. J Virol (2000) 1.20
Intrahepatic hepatitis C RNA levels do not correlate with degree of liver injury in patients with chronic hepatitis C. Hepatology (1996) 1.19
Fas-mediated apoptosis in human prostatic carcinoma cell lines. Cancer Res (1997) 1.19
False detection of negative-strand hepatitis C virus RNA. Lancet (1994) 1.18
Protection against zosteriform spread of herpes simplex virus by monoclonal antibodies. J Infect Dis (1991) 1.18
Characterization of CD40 signaling determinants regulating nuclear factor-kappa B activation in B lymphocytes. J Immunol (1997) 1.17
Specificity of human natural killer cells in limiting dilution culture for determinants of herpes simplex virus type 1 glycoproteins. J Virol (1986) 1.16
Different CD40-mediated signaling events require distinct CD40 structural features. J Immunol (1996) 1.15
Cutting edge: contrasting roles of TNF receptor-associated factor 2 (TRAF2) and TRAF3 in CD40-activated B lymphocyte differentiation. J Immunol (1999) 1.15
Pathogenicity in mice of herpes simplex virus type 2 mutants unable to express glycoprotein C. J Virol (1986) 1.14
Subpopulations of human T lymphocytes. VII. Cellular basis of concanavalin A-induced T cell-mediated suppression of immunoglobulin production by B lymphocytes from normal humans. Cell Immunol (1979) 1.13
Replication-defective herpes simplex virus vectors for gene transfer in vivo. Proc Natl Acad Sci U S A (1996) 1.12
On-road vehicle emissions: regulations, costs, and benefits. Science (1995) 1.11
In vivo expression of beta-galactosidase in hippocampal neurons by HSV-mediated gene transfer. Hum Gene Ther (1992) 1.11
Recombinant interleukin 2 therapy in severe combined immunodeficiency disease. Proc Natl Acad Sci U S A (1989) 1.11
Modulatory effects on immunoglobulin synthesis and secretion by lymphocytes from immunodeficient patients. J Clin Invest (1977) 1.11
Human natural killer cell recognition of herpes simplex virus type 1 glycoproteins: specificity analysis with the use of monoclonal antibodies and antigenic variants. J Immunol (1984) 1.11
Molecular pathogenesis of liver disease: an approach to hepatic inflammation, cirrhosis and liver transplant tolerance. Immunol Rev (2000) 1.11
Immunoregulatory effects of morphine on human lymphocytes. Clin Diagn Lab Immunol (1997) 1.10
Heavy chain-specific suppression of immunoglobulin synthesis and secretion by lymphocytes from patients with selective IgA deficiency. J Immunol (1980) 1.10